IVERIC bio EBIT

IVERIC bio (ISEE) currently reports a EBIT of $-230M as of March 2023. That compares with $-120M in the prior-year period — down 87.2% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore IVERIC bio's EBIT history and peer comparisons.

IVERIC bio's EBIT decreased from $-120M to $-230M — a 87.2% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IVERIC bio's EBIT of $-230M is lower than the Healthcare sector average of $99B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

IVERIC bio reported $-230M in EBIT as of March 2023. That compares with $-120M in the prior-year period — down 87.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-230M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for IVERIC bio, and consider following ISEE for alerts when major investors trade the stock.